Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.52 |
| ▸ | NAMPT | P43490 | 7/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.46 |
| ▸ | ITK | Q08881 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6091476 | 0.87 | KMT2A (0.46) | ROCK2ROCK1NAMPTRAB9AKDM4E | |
| SCHEMBL6096686 | 0.82 | EPHX1 (0.48) | NAMPTRAB9AKDRPTPN7HTT | |
| SCHEMBL6094221 | 0.82 | RAB9A (0.48) | ROCK2ROCK1NAMPTRAB9AHTT | |
| SCHEMBL6092098 | 0.82 | HSD17B10 (0.46) | ROCK2ROCK1ADORA2BADORA1RAB9A | |
| SCHEMBL4371236 | 0.81 | ROCK2 (0.47) | ROCK2ROCK1ADORA2BADORA1RAB9A | |
| SCHEMBL4363701 | 0.80 | ROCK2 (0.52) | ROCK2ROCK1NAMPTRAB9AIMPDH2 | |
| SCHEMBL4372959 | 0.78 | KDM4E (0.44) | ROCK2RAB9AKDM4E | |
| SCHEMBL6093269 | 0.78 | ROCK2 (0.51) | ROCK2ROCK1ADORA1RAB9AKDR | |
| SCHEMBL4368860 | 0.78 | ROCK2 (0.51) | ROCK2RAB9AKDRHTTKDM4E | |
| SCHEMBL20707804 | 0.77 | ADORA2A (0.46) | RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060036098-A1 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036098-A1 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | AR, SHBG, BRCA1 | ROCK2 1265/4885ROCK1 609/4885NAMPT 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.